Drugs / CTP-499
CTP-499
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03836222 | Feb → Jun 2018 | — | Processa Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01460199 | Aug → Dec 2011 | chronic kidney disease | Concert Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04800562 | Apr 2021 → Feb 2023 | necrobiosis lipoidica | Processa Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03698864 | Nov 2018 → Feb 2020 | necrobiosis lipoidica | Processa Pharmaceuticals | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01328821 Comparator | Mar → Apr 2011 | diabetic kidney disease | Concert Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01487109 Comparator | Jan 2012 → Jan 2015 | chronic kidney disease, type 2 diabetes mellitus | Concert Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTP-499 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01487109 ↗ |
| Known as | Deuterated s-lisofylline | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300766 ↗ |
| Known as | Lisophylline, (s)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL4300766 ↗ |
| Known as | PCS499 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03836222 ↗ |
| Modality | Small molecule | “PCS499, an oral deuterated pentoxifylline analog, may offer therapeutic benefit.” PMID 42054009 ↗ Jun 2026 |
| Route | Oral | “PCS499, 900 mg, orally twice daily for 6 months, with optional 6-month extension.” PMID 42054009 ↗ Jun 2026 |